{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:05:49Z","timestamp":1787504749349,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFA0802300"],"award-info":[{"award-number":["2019YFA0802300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.intimp.2022.109493","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T23:32:43Z","timestamp":1671060763000},"page":"109493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Contribution of IL-33\/ILC2-mediated Th2 cytokines during the progression of minimal change disease"],"prefix":"10.1016","volume":"114","author":[{"given":"Cui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intan","family":"Hakimah Binti Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109493_b0005","doi-asserted-by":"crossref","unstructured":"T.P. Andolino, J. Reid-Adam, Nephrotic syndrome, Pediatrics in review 36(3) (2015) 117-25; quiz 26, 29.","DOI":"10.1542\/pir.36-3-117"},{"issue":"5","key":"10.1016\/j.intimp.2022.109493_b0010","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.kint.2018.04.024","article-title":"Acute kidney injury complicating nephrotic syndrome of minimal change disease","volume":"94","author":"Meyrier","year":"2018","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.intimp.2022.109493_b0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrology : CJASN."},{"issue":"4","key":"10.1016\/j.intimp.2022.109493_b0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000464475","article-title":"The evolving role of rituximab in adult minimal change glomerulopathy","volume":"45","author":"Brown","year":"2017","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109493_b0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000442680","article-title":"Glomerular hypertrophy is a risk factor for relapse in minimal change disease patients","volume":"132","author":"Lee","year":"2016","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.intimp.2022.109493_b0030","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2012070734","article-title":"The treatment of minimal change disease in adults","volume":"24","author":"Hogan","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109493_b0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ni.3489","article-title":"Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis","volume":"17","author":"Klose","year":"2016","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109493_b0040","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.intimp.2022.109493_b0045","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10157-016-1325-1","article-title":"Minimal change nephrotic syndrome and prohibitin-2 gene polymorphism","volume":"21","author":"Sugimoto","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.intimp.2022.109493_b0050","doi-asserted-by":"crossref","unstructured":"A.H. Kim, J.J. Chung, S. Akilesh, A. Koziell, S. Jain, J.B. Hodgin, et al., B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement, JCI insight 2017;2(21).","DOI":"10.1172\/jci.insight.81836"},{"issue":"11","key":"10.1016\/j.intimp.2022.109493_b0055","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109493_b0060","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1681\/ASN.2016080877","article-title":"IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive Glomerulosclerosis","volume":"28","author":"Riedel","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109493_b0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcyt.2013.08.002","article-title":"Protective effects of mesenchymal stromal cells on adriamycin-induced minimal change nephrotic syndrome in rats and possible mechanisms","volume":"16","author":"Guo","year":"2014","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.intimp.2022.109493_b0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000486967","article-title":"miR-499 Ameliorates Podocyte Injury by Targeting Calcineurin in Minimal Change Disease","volume":"47","author":"Zhang","year":"2018","journal-title":"Am. J. Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109493_b0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods (San Diego, Calif)."},{"issue":"11","key":"10.1016\/j.intimp.2022.109493_b0080","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.3390\/ijms21114099","article-title":"Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury","volume":"21","author":"Sang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109493_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.NURSE.0000549719.61573.cd","article-title":"Minimal change disease: A case report","volume":"49","author":"Mitchell-Brown","year":"2019","journal-title":"Nursing"},{"issue":"2","key":"10.1016\/j.intimp.2022.109493_b0090","first-page":"214","article-title":"New insight in pathogenesis of podocyte disfunction in minimal change disease","volume":"45","author":"Liu","year":"2016","journal-title":"Zhejiang da xue xue bao Yi xue ban = J. Zhejiang Univ. Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.109493_b0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pcl.2018.08.006","article-title":"Nephrotic Syndrome","volume":"66","author":"Wang","year":"2019","journal-title":"Pediatr. Clin. North Am."},{"issue":"4","key":"10.1016\/j.intimp.2022.109493_b0100","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.kint.2018.10.032","article-title":"Wnt\/\u03b2-catenin links oxidative stress to podocyte injury and proteinuria","volume":"95","author":"Zhou","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2022.109493_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coph.2017.03.010","article-title":"New biologics in the treatment of rare glomerular diseases of childhood","volume":"33","author":"Cravedi","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109493_b0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/BOR.0000000000000578","article-title":"The immune podocyte","volume":"31","author":"Bhargava","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109493_b0115","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2310\/JIM.0b013e31826d8fcb","article-title":"IL-33: a potential therapeutic target in autoimmune diseases","volume":"60","author":"Wang","year":"2012","journal-title":"J. Investigative Med.: The Official Publ. Am. Federation Clin. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109493_b0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mmr.2015.4516","article-title":"IL-33 and kidney disease (Review)","volume":"13","author":"Yang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2022.109493_b0125","first-page":"3005","article-title":"Interleukin-18 binding protein attenuates renal injury of adriamycin-induced mouse nephropathy","volume":"12","author":"Dong","year":"2019","journal-title":"Int. J. Clin. Exp. Path."},{"issue":"1","key":"10.1016\/j.intimp.2022.109493_b0130","doi-asserted-by":"crossref","first-page":"e0227414","DOI":"10.1371\/journal.pone.0227414","article-title":"Efficacy of a mitochondrion-targeting agent for reducing the level of urinary protein in rats with puromycin aminonucleoside-induced minimal-change nephrotic syndrome","volume":"15","author":"Fujii","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.intimp.2022.109493_b0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/path.5512","article-title":"Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway","volume":"252","author":"Shen","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2022.109493_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118794","article-title":"LncRNA MALAT1\/microRNA let-7f\/KLF5 axis regulates podocyte injury in diabetic nephropathy","volume":"266","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2022.109493_b0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2017.05.001","article-title":"Innate lymphoid cell-derived cytokines in autoimmune diseases","volume":"83","author":"Li","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2022.109493_b0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coi.2014.01.013","article-title":"Regulation of the adaptive immune system by innate lymphoid cells","volume":"27","author":"Hepworth","year":"2014","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109493_b0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imr.12706","article-title":"The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms","volume":"286","author":"Kabata","year":"2018","journal-title":"Immunol. Rev."},{"issue":"25","key":"10.1016\/j.intimp.2022.109493_b0160","doi-asserted-by":"crossref","first-page":"10240","DOI":"10.1073\/pnas.1217158110","article-title":"Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells","volume":"110","author":"Klein Wolterink","year":"2013","journal-title":"PNAS"},{"issue":"10","key":"10.1016\/j.intimp.2022.109493_b0165","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.3390\/cells10102615","article-title":"Eosinophils, beyond IL-5","volume":"10","author":"Esnault","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.intimp.2022.109493_b0170","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bph.13139","article-title":"Microglial M1\/M2 polarization and metabolic states","volume":"173","author":"Orihuela","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109493_b0175","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri\u2010Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200978X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200978X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:45:11Z","timestamp":1761587111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692200978X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["S156757692200978X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109493","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of IL-33\/ILC2-mediated Th2 cytokines during the progression of minimal change disease","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109493"}}